Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 2
2009 11
2010 3
2011 3
2012 8
2013 10
2014 6
2015 11
2016 9
2017 14
2018 16
2019 11
2020 9
2021 11
2022 8
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Klümper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, Sikic D, Breyer J, Bolenz C, Zengerling F, Erben P, Schwamborn K, Wirtz RM, Horn T, Nagy D, Toma M, Kristiansen G, Büttner T, Hahn O, Grünwald V, Darr C, Erne E, Rausch S, Bedke J, Schlack K, Abbas M, Zschäbitz S, Schwab C, Mustea A, Adam P, Manseck A, Wullich B, Ritter M, Hartmann A, Gschwend J, Weichert W, Erlmeier F, Hölzel M, Eckstein M. Klümper N, et al. Among authors: wirtz rm. Clin Cancer Res. 2023 Apr 14;29(8):1496-1505. doi: 10.1158/1078-0432.CCR-22-1764. Clin Cancer Res. 2023. PMID: 36534531 Free PMC article.
Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.
Cox A, Klümper N, Stein J, Sikic D, Breyer J, Bolenz C, Roghmann F, Erben P, Wirtz RM, Wullich B, Ritter M, Hölzel M, Schwamborn K, Horn T, Gschwend J, Hartmann A, Weichert W, Erlmeier F, Eckstein M. Cox A, et al. Among authors: wirtz rm. Eur Urol. 2024 Apr;85(4):328-332. doi: 10.1016/j.eururo.2023.03.020. Epub 2023 Apr 6. Eur Urol. 2024. PMID: 37031005 Free article.
PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma.
Klümper N, Wüst L, Saal J, Ralser DJ, Zarbl R, Jarczyk J, Breyer J, Sikic D, Wullich B, Bolenz C, Roghmann F, Hölzel M, Ritter M, Strieth S, Hartmann A, Erben P, Wirtz RM, Landsberg J, Dietrich D, Eckstein M. Klümper N, et al. Among authors: wirtz rm. Oncoimmunology. 2023 Oct 19;12(1):2267744. doi: 10.1080/2162402X.2023.2267744. eCollection 2023. Oncoimmunology. 2023. PMID: 37868689 Free PMC article.
BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study.
Ecke TH, Meisl CJ, Schlomm T Prof, Rabien A, Labonté F, Rong D, Hofbauer S, Friedersdorff F Prof, Sommerfeldt L, Gagel N, Gössl A, Barski D, Otto T Prof, Grunewald CM, Niegisch G Prof, Hennig MJP, Kramer MW Prof, Koch S Prof, Roggisch J, Hallmann S, Weiß S, Waldner M, Graff J, Veltrup E, Linden F, Hake R, Eidt S, Wirtz RM. Ecke TH, et al. Among authors: wirtz rm. Urol Oncol. 2023 Dec;41(12):484.e17-484.e26. doi: 10.1016/j.urolonc.2023.06.013. Epub 2023 Jul 4. Urol Oncol. 2023. PMID: 37407421
Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive Microenvironment.
Busse A, Mochmann LH, Spenke C, Arsenic R, Briest F, Jöhrens K, Lammert H, Sipos B, Kühl AA, Wirtz R, Pavel M, Hummel M, Kaemmerer D, Baum RP, Grabowski P. Busse A, et al. Among authors: wirtz r. Cancers (Basel). 2020 Nov 19;12(11):3448. doi: 10.3390/cancers12113448. Cancers (Basel). 2020. PMID: 33228231 Free PMC article.
miRNA-26b Overexpression in Ulcerative Colitis-associated Carcinogenesis.
Benderska N, Dittrich AL, Knaup S, Rau TT, Neufert C, Wach S, Fahlbusch FB, Rauh M, Wirtz RM, Agaimy A, Srinivasan S, Mahadevan V, Rümmele P, Rapti E, Gazouli M, Hartmann A, Schneider-Stock R. Benderska N, et al. Among authors: wirtz rm. Inflamm Bowel Dis. 2015 Sep;21(9):2039-51. doi: 10.1097/MIB.0000000000000453. Inflamm Bowel Dis. 2015. PMID: 26083618 Free PMC article.
Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial).
Breyer J, Eckstein M, Sikic D, Wezel F, Roghmann F, Brehmer M, Wirtz RM, Jarczyk J, Erben P, Bahlinger V, Goldschmidt F, Fechner G, Chen J, Paxinos E, Bates M, Haas M, Zengerling F, Bolenz C, Burger M, Hartmann A, Kriegmair MC; BRIDGE Consortium e.V.. Breyer J, et al. Among authors: wirtz rm. Sci Rep. 2023 Sep 18;13(1):15437. doi: 10.1038/s41598-023-42088-z. Sci Rep. 2023. PMID: 37723173 Free PMC article.
The Role of CXCL13 and CXCL9 in Early Breast Cancer.
Razis E, Kalogeras KT, Kotsantis I, Koliou GA, Manousou K, Wirtz R, Veltrup E, Patsea H, Poulakaki N, Dionysopoulos D, Pervana S, Gogas H, Koutras A, Pentheroudakis G, Christodoulou C, Linardou H, Pavlakis K, Koletsa T, Pectasides D, Zagouri F, Fountzilas G. Razis E, et al. Among authors: wirtz r. Clin Breast Cancer. 2020 Feb;20(1):e36-e53. doi: 10.1016/j.clbc.2019.08.008. Epub 2019 Sep 5. Clin Breast Cancer. 2020. PMID: 31699671
C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
Klümper N, Sikic D, Saal J, Büttner T, Goldschmidt F, Jarczyk J, Becker P, Zeuschner P, Weinke M, Kalogirou C, Breyer J, Burger M, Nuhn P, Tully K, Roghmann F, Bolenz C, Zengerling F, Wirtz RM, Muders M, Kristiansen G, Bald T, Ellinger J, Wullich B, Hölzel M, Hartmann A, Erben P, Ritter M, Eckstein M. Klümper N, et al. Among authors: wirtz rm. Eur J Cancer. 2022 May;167:13-22. doi: 10.1016/j.ejca.2022.02.022. Epub 2022 Mar 30. Eur J Cancer. 2022. PMID: 35366569 Free article.
125 results